Neurologix' Ph II trial PD gene therapy gets go-ahead

Neurologix, a US biotechnology company engaged in the development of gene therapies for the brain and central nervous system, has received Institutional Review Board approval to begin recruiting and enrolling participants for a Phase II trial of its gene transfer approach to the treatment of advanced Parkinson's disease. The study is designed to evaluate the safety and efficacy of a novel non-dopaminergic approach for reestablishing motor function in PD patients who are sub-optimally responsive to drug therapies.

The randomized, double-blind, sham-procedure-controlled trial will involve up to 10 leading academic research centers across the USA, with the first sites being Massachusetts General Hospital and Wake Forest University Health Sciences. Neurologix expects to enroll a total of 40 participants in the study.